Card references

  1. National Vascular Disease Prevention Alliance. Guidelines for the management of absolute cardiovascular disease risk. 2012. [Online] (accessed 1 February 2017).
  2. Royal Australian College of General Practitioners. Guidelines for preventive activities in general practice (9th edition). East Melbourne: RACGP, 2016. [Online] (accessed 1 December 2016).
  3. Cholesterol Treatment Trialists and Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90. [PubMed].
  4. National Institute for Health and Care Excellence. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: National Clinical Guideline Centre (UK), 2014. [Online] (accessed 31 January 2017).
  5. Wan Q, Zwar N, Vagholkar S, et al. Cardiovascular absolute risk assessment and management Engagement and outcomes in general practice patients. Aust Fam Physician 2010;39:954-8. [PubMed].
  6. Royal Australian College of General Practitioners. 5 things that clinicians and consumers should question. Sydney: Choosing Wisely Australia, 2015. [Online] (accessed 13 February 2017).
  7. NPS MedicineWise. Pre-treatment absolute CV risk of patients prescribed statins; MedicineInsight cohort. MedicineInsight. Sydney: NPS MedicineWise, 2017.
  8. Cardiovascular Expert Group. Therapeutic Guidelines: Dyslipidaemia. West Melbourne, Victoria: Therapeutic Guidelines Ltd, 2012. [eTG] (accessed 22 December 2016).
  9. National Heart Foundation of Australia, Cardiac Society of Australia and New Zealand. Reducing risk in heart disease: an expert guide to clinical practice for secondary prevention of coronary heart disease. Melbourne: National Heart Foundation of Australia, 2012. [Online] (accessed 13 February 2017).
  10. Chew DP, Scott IA, Cullen L, et al. National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of acute coronary syndromes 2016. Heart Lung Circ 2016;25:895-951. [PubMed].
  11. Maningat P, Gordon BR, Breslow JL. How do we improve patient compliance and adherence to long-term statin therapy? Curr Atheroscler Rep 2012;15:291. [PubMed].
  12. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016;37:2999-3058. [PubMed].
  13. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials. J Am Coll Cardiol 2014;64:485-94. [PubMed].
  14. Nordestgaard BG, Langsted A, Mora S, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016. [PubMed].
  15. Sparke C. Path labs move to non-fasting lipid testing. Australian Doctor. Sydney: Cirrus Media, 2016. [Online] (accessed 25 January 2017).
  16. Turin A, Pandit J, Stone NJ. Statins and nonadherence: Should we RELATE better? J Cardiovasc Pharmacol Ther 2015;20:447-56. [PubMed].
  17. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty Ltd, 2017. [Online] (accessed 7 February 2017).
  18. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423. [PubMed].
  19. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012;223:251-61. [PubMed].
  20. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97. [PubMed].
  21. Amgen. Repatha (evolocumab) Product Information. North Ryde: Amgen Australia Pty Ltd, 2015. [TGA online] (accessed 31 January 2017).
  22. Sanofi-Aventis. Product Information, Praluent. Macquarie Park: Sanofi-Aventis Australia Pty Ltd, 2016. [Online] (accessed 1 February 2017).
  23. Pharmaceutical Benefits Advisory Committee. March 2016 PBAC Meeting - Positive Recommendations. Canberra: Government of Australia, 2016. [Online] (accessed 22 December 2016).
  24. Navarese E, Kołodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: A systematic review and meta-analysis. Ann Intern Med 2015;163:40-51. [PubMed].
  25. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017. [PubMed].
  26. Cainzos-Achirica M, Martin SS, Cornell JE, et al. PCSK9 inhibitors: A new era in lipid-lowering treatment? Ann Intern Med 2015;163:64-5. [PubMed].
  27. Pandor A, Ara RM, Tumur I, et al. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. J Intern Med 2009;265:568-80. [PubMed].
  28. Balk EM, Adam GP, Langberg V, et al. Omega-3 fatty acids and cardiovascular disease: An updated systematic review. Evidence Report/Technology Assessment. Rockville, MD: Agency for Healthcare Research and Quality, 2016; 223. [Online] (accessed 10 February 2017).